AU2957697A - Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for the normalization of serum lipids - Google Patents

Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for the normalization of serum lipids

Info

Publication number
AU2957697A
AU2957697A AU29576/97A AU2957697A AU2957697A AU 2957697 A AU2957697 A AU 2957697A AU 29576/97 A AU29576/97 A AU 29576/97A AU 2957697 A AU2957697 A AU 2957697A AU 2957697 A AU2957697 A AU 2957697A
Authority
AU
Australia
Prior art keywords
nhe
normalization
medicament
inhibitors
exchanger
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU29576/97A
Other versions
AU722166B2 (en
Inventor
Eugen Falk
Hans-Willi Jansen
Oliver Jung
Heinz-Werner Kleemann
Werner Kramer
Hans Jochen Lang
Wolfgang Linz
Hans-Ludwig Schafer
Bernward Scholkens
Jan-Robert Schwark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19712636A external-priority patent/DE19712636A1/en
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU2957697A publication Critical patent/AU2957697A/en
Application granted granted Critical
Publication of AU722166B2 publication Critical patent/AU722166B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU29576/97A 1996-06-03 1997-05-20 Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for the normalization of serum lipids Ceased AU722166B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19622222A DE19622222A1 (en) 1996-06-03 1996-06-03 Use of sodium=proton exchange inhibitor
DE19622222 1996-06-03
DE19712636A DE19712636A1 (en) 1997-03-26 1997-03-26 Use of inhibitor of sodium/proton exchange to treat hyperlipidaemia
DE19712636 1997-03-26
PCT/EP1997/002548 WO1997046226A2 (en) 1996-06-03 1997-05-20 USE OF INHIBITORS OF THE CELLULAR Na+/H+ EXCHANGER (NHE) FOR PREPARING A MEDICAMENT FOR NORMALIZING SERUM LIPIDS

Publications (2)

Publication Number Publication Date
AU2957697A true AU2957697A (en) 1998-01-05
AU722166B2 AU722166B2 (en) 2000-07-20

Family

ID=26026256

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29576/97A Ceased AU722166B2 (en) 1996-06-03 1997-05-20 Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for the normalization of serum lipids

Country Status (23)

Country Link
EP (1) EP0918515B1 (en)
JP (1) JP4527811B2 (en)
KR (1) KR100511711B1 (en)
CN (1) CN1221339A (en)
AR (1) AR007353A1 (en)
AT (1) ATE293965T1 (en)
AU (1) AU722166B2 (en)
BR (1) BR9709516A (en)
CA (1) CA2257299A1 (en)
DE (2) DE19622222A1 (en)
DK (1) DK0918515T3 (en)
ES (1) ES2241049T3 (en)
IL (1) IL126935A0 (en)
NO (1) NO985480L (en)
NZ (1) NZ333095A (en)
PL (1) PL189950B1 (en)
PT (1) PT918515E (en)
RU (1) RU2211032C2 (en)
SI (1) SI0918515T1 (en)
SK (1) SK165898A3 (en)
TR (1) TR199802505T2 (en)
WO (1) WO1997046226A2 (en)
ZA (1) ZA974828B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
US6011059A (en) * 1997-12-24 2000-01-04 Bristol-Myers Squibb Company Acyl guanidine sodium/proton exchange inhibitors and method
DE19859727A1 (en) 1998-12-23 2000-06-29 Aventis Pharma Gmbh The use of inhibitors of the sodium-hydrogen exchanger for the manufacture of a medicament for the prevention of age-related organ dysfunctions, age-related illnesses for the prolongation of life
WO2000064445A1 (en) 1999-04-23 2000-11-02 Bristol-Myers Squibb Company Bicyclic acyl guanidine sodium/proton exchange inhibitors and method
DE19945302A1 (en) * 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenyl derivatives as NHE-3 inhibitors
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
FR2856062B1 (en) * 2003-06-12 2005-11-11 Aventis Pharma Sa 3-GUANIDINOCARBONYL-HETEROCYCLE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
US7230007B2 (en) 2003-06-12 2007-06-12 Sanofi-Aventis Deutschland Gmbh Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
NZ544671A (en) * 2003-06-26 2009-02-28 Biotron Ltd Antiviral compounds and methods
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
ES2319461T3 (en) 2005-02-10 2009-05-07 Bristol-Myers Squibb Company DIHYDROQUINAZOLINONES AS MODULATORS OF 5HT.
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (en) 2008-05-29 2009-12-31 Bristol Myers Squibb Co HAVE HYDROXYSUSTITUTED PYRIMIDINES AS NON-BASIC MELANIN-CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
EA201101231A1 (en) 2009-03-27 2012-06-29 Бристол-Майерс Сквибб Компани METHODS TO PREVENT OR REDUCE THE RISK OF MORTALITY
CA2787785C (en) 2010-01-28 2018-03-06 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
AU2012253402A1 (en) 2011-05-12 2013-05-02 Proteostasis Therapeutics, Inc. Proteostasis regulators
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
EP2892896B1 (en) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
JP2021530517A (en) 2018-07-19 2021-11-11 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Methods of Treating HFpEF with Dapagliflozin, and Compositions Containing Dapagliflozin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110817A (en) * 1988-10-21 1992-05-05 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
US4920123A (en) * 1988-10-21 1990-04-24 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
WO1991012799A1 (en) * 1990-02-28 1991-09-05 The Upjohn Company Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
EP0612723B1 (en) * 1993-02-20 1997-08-27 Hoechst Aktiengesellschaft Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them
DE4318658A1 (en) * 1993-06-04 1994-12-08 Hoechst Ag Substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, and medicament containing them
DE4325822A1 (en) * 1993-07-31 1995-02-02 Hoechst Ag Substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, and medicament containing them
IL114670A0 (en) * 1994-08-05 1995-11-27 Fujisawa Pharmaceutical Co Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof

Also Published As

Publication number Publication date
EP0918515B1 (en) 2005-04-27
PL330412A1 (en) 1999-05-10
JP4527811B2 (en) 2010-08-18
AR007353A1 (en) 1999-10-27
ATE293965T1 (en) 2005-05-15
BR9709516A (en) 1999-08-10
DE59712287D1 (en) 2005-06-02
CA2257299A1 (en) 1997-12-11
TR199802505T2 (en) 1999-04-21
PT918515E (en) 2005-06-30
DE19622222A1 (en) 1997-12-04
WO1997046226A2 (en) 1997-12-11
SI0918515T1 (en) 2005-12-31
SK165898A3 (en) 1999-05-07
AU722166B2 (en) 2000-07-20
KR20000016240A (en) 2000-03-25
ES2241049T3 (en) 2005-10-16
CN1221339A (en) 1999-06-30
EP0918515A2 (en) 1999-06-02
ZA974828B (en) 1997-12-03
WO1997046226A3 (en) 1998-03-05
DK0918515T3 (en) 2005-08-15
IL126935A0 (en) 1999-09-22
JP2000506906A (en) 2000-06-06
NO985480D0 (en) 1998-11-24
KR100511711B1 (en) 2005-12-26
PL189950B1 (en) 2005-10-31
RU2211032C2 (en) 2003-08-27
NO985480L (en) 1999-01-28
NZ333095A (en) 2000-08-25

Similar Documents

Publication Publication Date Title
AU2957697A (en) Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for the normalization of serum lipids
AU3532195A (en) Medicaments
AU5706499A (en) Planar ortho-mode transducer
AU1667795A (en) Pharmaceutical piperazine compounds
AU4606796A (en) Chewable dosage forms
AU2615695A (en) Hydroxamic acid derivatives
AU1667595A (en) Pharmaceutical piperazine compounds
AU3107795A (en) Inhibitors of the benzamidine type
AU2662588A (en) Compressor discharge muffler having cover plate
AU2728388A (en) Gas conditioning
AU1372097A (en) Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for respiratory stimulation
AU3810495A (en) Process for the manufacture of n-phosphonomethylglycine
AU577446B2 (en) Compressor valve plate
AU3189995A (en) Aluminium-immersed assembly for aluminium production cells
AU6194298A (en) A process for the preparation of moenomycin A
AU6581386A (en) Nonaromatic fluoroallylamine MAO inhibitors
AU4446889A (en) Ameliorating agent for dysmenesia
AU4765090A (en) Certain pyrrolylphenyl-substituted hydroxamic acid derivatives
AU1968688A (en) Orally active antiandrogens
AU1322388A (en) Pipeline conditioning
AU1014388A (en) Refrigerant compressor
AU1014488A (en) Refrigerant compressor
AU3986595A (en) Production of water-less lithographic plates
AU1667695A (en) Pharmaceutical piperazine compounds
HUP0001879A3 (en) Use of inhibitors of the cellular na+/h+ exchanger (nhe) for preparing a medicament for normalizing serum lipids

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)